Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1255-1263

  Carol, Hernan ^a   Lock, Richard ^a   Houghton, Peter J ^b   Morton, Christopher L ^b   Kolb, E Anders ^c   Gorlick, Richard ^c   Reynolds, C Patrick ^d   Maris, John M ^e   Keir, Stephen T ^f   Billups, Catherine A ^b   Smith, Malcolm A ^g  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Ispinesib; Preclinical testing

Indexed keywords

ISPINESIB; KINESIN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; EWING SARCOMA; FEMALE; HUMAN; MOUSE; NEPHROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; TUMOR CELL LINE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL LEUKEMIA; GLIOBLASTOMA; INTRAPERITONEAL DRUG ADMINISTRATION; MITOSIS SPINDLE; MOUSE MUTANT; PATHOLOGY; RHABDOMYOSARCOMA; SINGLE BLIND PROCEDURE;

ANIMALS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; FEMALE; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRAPERITONEAL; KINESIN; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, SCID; MITOTIC SPINDLE APPARATUS; OSTEOSARCOMA; QUINAZOLINES; RHABDOID TUMOR; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SINGLE-BLIND METHOD; TUMOR STEM CELL ASSAY; WILMS TUMOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449728074     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22056     Document Type: Article

References (32)

1. Jackson JR, Patrick DR, Dar MM, et al., Targeted anti-mitotic therapies: Can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-117.
2. Vale RD, Milligan RA. The way things move: Looking under the hood of molecular motor proteins. Science 2000;288:88-95.
3. Blangy A, Lane HA, d'Herin P, et al., Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-1169.
4. Jiang C, You Q, Li Z, et al., Kinesin spindle protein Inhibitors as anticancer agents. Expert Opin Ther Pat 2006;16:1517-1532.
5. Yan Y, Sardana V, Xu B, et al., Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J Mol Biol 2004;335:547-554.
6. Sakowicz R, Finer JT, Beraud C, et al., Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-3280.
7. Luo L, Carson JD, Dhanak D, et al., Mechanism of inhibition of human KSP by monastrol: Insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry 2004;43:15258-15266.
8. Skoufias DA, DeBonis S, Saoudi Y, et al., S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. J Biol Chem 2006;281:17559-17569.
9. Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67:237-245.
10. Burris HA, LoRusso P, Jones S, et al., Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. J Clin Oncol 2004;22: Abstr #2004.
11. Chu QS, Holen KD, Rowinsky EK, et al., Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. J Clin Oncol 2004;22: Abstr #2078.
12. Heath EI, Alousi A, Eder JP, et al., Aphase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. J Clin Oncol 2006;24: Abstr #2026.
13. El-Khoueiry AB, Iqbal S, Singh DA, et al., A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J Clin Oncol 2006;24: Abstr #3595.
14. Philco M, Falcon S, Gomez H, et al., A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2008;26: Abstr #1143.
15. Holen KD, Belani CP, Wilding G, et al., Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. J Clin Oncol 2006;24:Abstr #2000.
16. Stein MN, Rubin EH, Scott PD, et al., Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients. J Clin Oncol 2006;24: Abstr #2001.
17. Johnson RK, McCabe FL, Caulder E, et al., SB-715992, a potent and selective inhibitor of the mitotic kinesin KSP, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Annu Meet Am Assoc Cancer Res 2002;43:269.
18. Keshelava N, Frgala T, Krejsa J, et al., DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005;110:139-153.
19. Houghton PJ, Morton CL, Kolb EA, et al., Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:37-45.
20. Friedman HS, Colvin OM, Skapek SX, et al., Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
21. Graham C, Tucker C, Creech J, et al., Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
22. Peterson JK, Tucker C, Favours E, et al., In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
23. Liem NL, Papa RA, Milross CG, et al., Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
24. Houghton PJ, Morton CL, Tucker C, et al., The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
25. Paull KD, Lin CM, Malspeis L, et al., Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992;52:3892-3900.
26. DeBonis S, Skoufias DA, Lebeau L, et al., In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 2004;3:1079-1090.
27. Souid A, Dubowy RL, Triplett DG, et al., Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992):AChildren's Oncology Group phase I consortium study. J Clin Oncol 2008;26: Abstr #10014.
28. Rieder CL, Maiato H. Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004;7:637-651.
29. Tang PA, Siu LL, Chen EX, et al., Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008;26:257-264.
30. Knox JJ, Gill S, Synold TW, et al., A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008;26:265-272.
31. Lee CW, Belanger K, Rao SC, et al., A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008;26:249-255.
32. CytoKinetics I. CytoKinetics Announces Data From Phase II Clinical Trial of Ispinesib in Breast Cancer. Press Release 2007.